keyword
https://read.qxmd.com/read/38654033/real-life-experience-on-the-use-of-remdesivir-in-patients-admitted-to-covid-19-in-two-referral-italian-hospital-a-propensity-score-matched-analysis
#21
JOURNAL ARTICLE
Nicola Veronese, Francesco Di Gennaro, Luisa Frallonardo, Stefano Ciriminna, Roberta Papagni, Luca Carruba, Diletta Agnello, Giuseppina De Iaco, Nicolò De Gennaro, Giuseppina Di Franco, Liliana Naro, Gaetano Brindicci, Angelo Rizzo, Davide Fiore Bavaro, Maria Chiara Garlisi, Carmen Rita Santoro, Fabio Signorile, Flavia Balena, Pasquale Mansueto, Eugenio Milano, Lydia Giannitrapani, Deborah Fiordelisi, Michele Fabiano Mariani, Andrea Procopio, Rossana Lattanzio, Anna Licata, Laura Vernuccio, Simona Amodeo, Giacomo Guido, Francesco Vladimiro Segala, Mario Barbagallo, Annalisa Saracino
Remdesivir (RDV) was the first Food and Drug Administration (FDA)-approved medication for COVID-19, with discordant data on efficacy in reducing mortality risk and disease progression. In the context of a dynamic and rapidly changing pandemic landscape, the utilization of real-world evidence is of utmost importance. The objective of this study is to evaluate the impact of RDV on patients who have been admitted to two university referral hospitals in Italy due to COVID-19. All patients older than 18 years and hospitalized at two different universities (Bari and Palermo) were enrolled in this study...
April 23, 2024: Scientific Reports
https://read.qxmd.com/read/38653825/analysis-of-the-action-mechanisms-and-targets-of-herbal-anticonvulsants-highlights-opportunities-for-therapeutic-engagement-with-refractory-epilepsy
#22
REVIEW
Sobia Tabassum, Susan Shorter, Saak V Ovsepian
Epilepsy is a neurological disorder characterized by spontaneous and recurring seizures. It poses significant therapeutic challenges due to diverse etiology, pathobiology, and pharmacotherapy-resistant variants. The anticonvulsive effects of herbal leads with biocompatibility and toxicity considerations have attracted much interest, inspiring mechanistic analysis with the view of their use for engagement of new targets and combination with antiseizure pharmacotherapies. This article presents a comprehensive overview of the key molecular players and putative action mechanisms of the most common antiepileptic herbals demonstrated in tissue culture and preclinical models...
April 24, 2024: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
https://read.qxmd.com/read/38653561/long-term-effectiveness-and-safety-of-upadacitinib-for-japanese-patients-with-moderate-to-severe-atopic-dermatitis-a-real-world-clinical-study
#23
JOURNAL ARTICLE
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
BACKGROUND: Previous clinical trials presented efficacy and safety of Janus kinase 1 inhibitor upadacitinib through 52 weeks for moderate-to-severe atopic dermatitis (AD). OBJECTIVES: To assess the effectiveness and safety of upadacitinib through 48 weeks in real-world clinical practice for Japanese AD patients (aged ≥12 years). METHODS: This retrospective study included 287 patients with moderate-to severe AD treated with 15 mg ( n  = 216) or 30 mg ( n  = 71) of upadacitinib daily...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38653371/pleiotropic-role-of-gas6-in-cardioprotection-against-ischemia-reperfusion-injury
#24
JOURNAL ARTICLE
Chenxi Lu, Yanbin Song, Xiaopeng Wu, Wangrui Lei, Junmin Chen, Xin Zhang, Qiong Liu, Chao Deng, Zhenxing Liang, Ying Chen, Jun Ren, Yang Yang
INTRODUCTION: Myocardial ischemia-reperfusion (IR) injury is a common medical issue contributing to the onset and progression of ischemic heart diseases (IHD). Growth arrest-specific gene 6 (GAS6) is vitamin K-dependent secretory protein, to promote cell proliferation and inhibit inflammation and apoptosis through binding with Tyro3, Axl, and Mertk (TAM) receptors. OBJECTIVES: Our study aimed to examine the effect of GAS6 pathways activation as a potential new treatment in myocardial ischemia-reperfusion (IR) injury...
April 21, 2024: Journal of Advanced Research
https://read.qxmd.com/read/38653188/active-surveillance-pharmacovigilance-for-clostridioides-difficile-infection-and-gastrointestinal-bleeding-an-analytic-framework-based-on-case-control-studies
#25
JOURNAL ARTICLE
Ravy K Vajravelu, Amy R Byerly, Robert Feldman, Scott D Rothenberger, Robert E Schoen, Walid F Gellad, James D Lewis
BACKGROUND: Active surveillance pharmacovigilance is an emerging approach to identify medications with unanticipated effects. We previously developed a framework called pharmacopeia-wide association studies (PharmWAS) that limits false positive medication associations through high-dimensional confounding adjustment and set enrichment. We aimed to assess the transportability and generalizability of the PharmWAS framework by using medical claims data to reproduce known medication associations with Clostridioides difficile infection (CDI) or gastrointestinal bleeding (GIB)...
April 22, 2024: EBioMedicine
https://read.qxmd.com/read/38653154/the-pathological-mechanisms-and-potential-therapeutic-drugs-for-myocardial-ischemia-reperfusion-injury
#26
REVIEW
Shuo Zhang, Fei Yan, Fei Luan, Yun Chai, Na Li, Yu-Wei Wang, Zhen-Lin Chen, Ding-Qiao Xu, Yu-Ping Tang
BACKGROUND: Cardiovascular disease is the main cause of death and disability, with myocardial ischemia being the predominant type that poses a significant threat to humans. Reperfusion, an essential therapeutic approach, promptly reinstates blood circulation to the ischemic myocardium and stands as the most efficacious clinical method for myocardial preservation. Nevertheless, the restoration of blood flow associated with this process can potentially induce myocardial ischemia-reperfusion injury (MIRI), thereby diminishing the effectiveness of reperfusion and impacting patient prognosis...
April 16, 2024: Phytomedicine
https://read.qxmd.com/read/38653064/deepseq2drug-an-expandable-ensemble-end-to-end-anti-viral-drug-repurposing-benchmark-framework-by-multi-modal-embeddings-and-transfer-learning
#27
JOURNAL ARTICLE
Weidun Xie, Jixiang Yu, Lei Huang, Lek Shyuen For, Zetian Zheng, Xingjian Chen, Yuchen Wang, Zhichao Liu, Chengbin Peng, Ka-Chun Wong
Drug repurposing is promising in multiple scenarios, such as emerging viral outbreak controls and cost reductions of drug discovery. Traditional graph-based drug repurposing methods are limited to fast, large-scale virtual screens, as they constrain the counts for drugs and targets and fail to predict novel viruses or drugs. Moreover, though deep learning has been proposed for drug repurposing, only a few methods have been used, including a group of pre-trained deep learning models for embedding generation and transfer learning...
April 17, 2024: Computers in Biology and Medicine
https://read.qxmd.com/read/38652877/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative-breast-cancer-results-from-the-phase-i-tropion-pantumor01-study
#28
JOURNAL ARTICLE
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika P Hamilton, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
PURPOSE: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker. PATIENTS AND METHODS: TROPION-PanTumor01 (ClinicalTrials.gov identifier: NCT03401385) is a phase I, dose-escalation, and dose-expansion study evaluating Dato-DXd in patients with previously treated solid tumors...
April 23, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38652738/rapid-screening-of-new-psychoactive-substances-using-pdart-qqq-ms
#29
JOURNAL ARTICLE
Wei-Hsin Hsu, Kai-Wen Cheng, Tzu-Hsuan Feng, Ju-Yu Chen, Guan-Yuan Chen, Lian-Yu Chen, Te I Weng, Cheng-Chih Hsu
Drug abuse is a severe social problem worldwide. Particularly, the issue of new psychoactive substances (NPSs) have increasingly emerged. NPSs are structural or functional analogs of traditional illicit drugs, such as cocaine, cannabis, and amphetamine; these molecules provide the same or more severe neurological effects. Usually, immunoassays are utilized in the preliminary screening method. However, NPSs have poor detectability in commercially available immunoassay kits. Meanwhile, various chromatography combined with the mass spectrometry platform have been developed to quantify NPSs...
April 23, 2024: Journal of the American Society for Mass Spectrometry
https://read.qxmd.com/read/38652734/gaussian-accelerated-molecular-dynamics-simulations-facilitate-prediction-of-the-permeability-of-cyclic-peptides
#30
JOURNAL ARTICLE
Nicolas Frazee, Kyle R Billlings, Blake Mertz
Despite their widespread use as therapeutics, clinical development of small molecule drugs remains challenging. Among the many parameters that undergo optimization during the drug development process, increasing passive cell permeability (i.e., log(P)) can have some of the largest impact on potency. Cyclic peptides (CPs) have emerged as a viable alternative to small molecules, as they retain many of the advantages of small molecules (oral availability, target specificity) while being highly effective at traversing the plasma membrane...
2024: PloS One
https://read.qxmd.com/read/38652454/role-of-mucositis-in-predicting-gut-microbiota-composition-in-people-with-cancer
#31
JOURNAL ARTICLE
Jacqui S Scott, Anna Li, Hannah R Wardill
PURPOSE OF REVIEW: Disruption of the precious ecosystem of micro-organisms that reside in the gut - the gut microbiota - is rapidly emerging as a key driver of adverse side effects/toxicities caused by numerous anti-cancer agents. Although the contribution of the gut microbiota to these toxicities is understood with ever increasing precision, the cause of microbial disruption (dysbiosis) remains poorly understood. Here, we discuss current evidence on the cause(s) of dysbiosis after cancer therapy, positioning breakdown of the intestinal mucosa (mucositis) as a central cause...
April 23, 2024: Current Opinion in Supportive and Palliative Care
https://read.qxmd.com/read/38652426/antibody-drug-conjugates-in-urological-cancers-a-review-of-the-current-landscape
#32
REVIEW
Aruni Ghose, Patricia Lapitan, Vedika Apte, Adheesh Ghosh, Abhinav Kandala, Sreejana Basu, Jo Parkes, Sayali D Shinde, Stergios Boussios, Anand Sharma, Prantik Das, Nikhil Vasdev, Sara E Rebuzzi, Yüksel Ürün, Ravindran Kanesvaran, Akash Maniam, Giuseppe L Banna
PURPOSE OF REVIEW: Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody-drug conjugate (ADC) development, emphasising their transformative potential in cancer care. RECENT FINDINGS: ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA's approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer...
April 23, 2024: Current Oncology Reports
https://read.qxmd.com/read/38652356/current-progress-challenges-and-prospects-in-the-development-of-covid-19-vaccines
#33
REVIEW
Congrui Zhu, Shengmei Pang, Jiaqi Liu, Qiangde Duan
The COVID-19 pandemic has resulted in over 772 million confirmed cases, including nearly 7 million deaths, according to the World Health Organization (WHO). Leveraging rapid development, accelerated vaccine approval processes, and large-scale production of various COVID-19 vaccines using different technical platforms, the WHO declared an end to the global health emergency of COVID-19 on May 5, 2023. Current COVID-19 vaccines encompass inactivated, live attenuated, viral vector, protein subunit, nucleic acid (DNA and RNA), and virus-like particle (VLP) vaccines...
April 23, 2024: Drugs
https://read.qxmd.com/read/38652355/recent-united-states-developments-in-the-pharmacological-treatment-of-dry-eye-disease
#34
REVIEW
David Valdés-Arias, Elyana V T Locatelli, Paula A Sepulveda-Beltran, Simran Mangwani-Mordani, Juan Carlos Navia, Anat Galor
Dry eye disease (DED) can arise from a variety of factors, including inflammation, meibomian gland dysfunction (MGD), and neurosensory abnormalities. Individuals with DED may exhibit a range of clinical signs, including tear instability, reduced tear production, and epithelial disruption, that are driven by different pathophysiological contributors. Those affected often report a spectrum of pain and visual symptoms that can impact physical and mental aspects of health, placing an overall burden on an individual's well-being...
April 23, 2024: Drugs
https://read.qxmd.com/read/38652352/neuronal-mitochondrial-calcium-uniporter-mcu-deficiency-is-neuroprotective-in-hyperexcitability-by-modulation-of-metabolic-pathways-and-ros-balance
#35
JOURNAL ARTICLE
Laura Bierhansl, Lukas Gola, Venu Narayanan, Andre Dik, Sven G Meuth, Heinz Wiendl, Stjepana Kovac
Epilepsy is one of the most common neurological disorders in the world. Common epileptic drugs generally affect ion channels or neurotransmitters and prevent the emergence of seizures. However, up to a third of the patients suffer from drug-resistant epilepsy, and there is an urgent need to develop new therapeutic strategies that go beyond acute antiepileptic (antiseizure) therapies towards therapeutics that also might have effects on chronic epilepsy comorbidities such as cognitive decline and depression. The mitochondrial calcium uniporter (MCU) mediates rapid mitochondrial Ca2+ transport through the inner mitochondrial membrane...
April 23, 2024: Molecular Neurobiology
https://read.qxmd.com/read/38652349/factors-associated-with-inclusion-of-japan-in-phase-i-multiregional-clinical-trials-in-oncology
#36
JOURNAL ARTICLE
Akio Maki, Mamoru Narukawa
BACKGROUND: Early inclusion of Japan in the global development program could be a key factor in reducing the drug lag, making participation in phase I multiregional clinical trials (Ph. I MRCTs) an important consideration for oncology drug development in Japan. We aimed to investigate the factors associated with the inclusion of Japan in Ph. I MRCTs in oncology. METHODS: We compared the trial design, target population, type of primary tested drug, trial conduct profile, and sponsor profile for Ph...
April 23, 2024: Therapeutic Innovation & Regulatory Science
https://read.qxmd.com/read/38652115/interplay-of-precision-therapeutics-and-md-study-calocybe-indica-s-potentials-against-cervical-cancer-and-its-interaction-with-vegf-via-octadecanoic-acid
#37
JOURNAL ARTICLE
Suhana Datta, Preeti Verma, Bikram Dhara, Rita Kundu, Swastika Maitra, Arup Kumar Mitra, Mohd Shahnawaz Khan, Torki A Zughaibi, Shams Tabrez, Ajoy Kumer
The evolving landscape of personalized medicine necessitates a shift from traditional therapeutic interventions towards precision-driven approaches. Embracing this paradigm, our research probes the therapeutic efficacy of the aqueous crude extract (ACE) of Calocybe indica in cervical cancer treatment, merging botanical insights with advanced molecular research. We observed that ACE exerts significant influences on nuclear morphology and cell cycle modulation, further inducing early apoptosis and showcasing prebiotic attributes...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38652038/a-first-in-human-phase-1-study-of-a-tumor-directed-rna-interference-drug-against-hif2%C3%AE-in-patients-with-advanced-clear-cell-renal-cell-carcinoma
#38
JOURNAL ARTICLE
James Brugarolas, Gregory Obara, Kathryn E Beckermann, Brian Rini, Elaine T Lam, James Hamilton, Thomas Schluep, Min Yi, So Wong, Zhongping Lily Mao, Erick Gamelin, Nizar M Tannir
PURPOSE: ARO-HIF2 is an siRNA drug designed to selectively target hypoxia-inducible factor-2α (HIF2α) interrupting downstream pro-oncogenic signaling in clear cell renal cell carcinoma (ccRCC). The aims of this Phase 1 study (AROHIF21001) were to evaluate safety, tolerability, pharmacokinetics, and establish a recommended Phase 2 dose. PATIENTS AND METHODS: Subjects with ccRCC and progressive disease after at least 2 prior therapies that included VEGF and immune checkpoint inhibitors were progressively enrolled into dose-escalation cohorts of ARO-HIF2 administered intravenously at 225, 525, or 1,050 mg weekly...
April 23, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38651962/-the-revolution-of-ai-in-drug-development
#39
JOURNAL ARTICLE
Philippe Moingeon, Christiane Garbay, Muriel Dahan, Irène Fermont, Ali Benmakhlouf, Alain Gouyette, Pierre Poitou, Alain Saint-Pierre
Artificial intelligence and machine learning enable the construction of predictive models, which are currently used to assist in decision-making throughout the process of drug discovery and development. These computational models can be used to represent the heterogeneity of a disease, identify therapeutic targets, design and optimize drug candidates, and evaluate the efficacy of these drugs on virtual patients or digital twins. By combining detailed patient characteristics with the prediction of potential drug-candidate properties, artificial intelligence promotes the emergence of a "computational" precision medicine, allowing for more personalized treatments, better tailored to patient specificities with the aid of such predictive models...
April 2024: Médecine Sciences: M/S
https://read.qxmd.com/read/38651929/azole-resistance-mechanisms-and-population-structure-of-the-human-pathogen-aspergillus-fumigatus-on-retail-plant-products
#40
JOURNAL ARTICLE
Caroline Wang, Natalie Miller, Douglas Vines, Paul M Severns, Michelle Momany, Marin T Brewer
Aspergillus fumigatus is a ubiquitous saprotroph and human-pathogenic fungus that is life-threatening to the immunocompromised. Triazole-resistant A. fumigatus was found in patients without prior treatment with azoles, leading researchers to conclude that resistance had developed in agricultural environments where azoles are used against plant pathogens. Previous studies have documented azole-resistant A. fumigatus across agricultural environments, but few have looked at retail plant products. Our objectives were to determine if azole-resistant A...
April 23, 2024: Applied and Environmental Microbiology
keyword
keyword
110054
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.